UPDATE: Predicine Introduces PredicineCARE™ NGS Kit for Tumor Profiling
HAYWARD, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc., a leading molecular insights company, announced the release of its...
Pharmaceutical
PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission
TARRYTOWN, New York, April 11, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on...
Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on April 10, 2024,...
Nurix Therapeutics Announces Proposed Public Offering
SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein...
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
Nes-Ziona, Israel, April 11, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC Leuven, BELGIUM – April 11, 2024 – 07:00 PM CET Oxurion...
Cosmo and Medtronic Unveil the Future of AI in GI: Genius Summit 2024 Reveals Innovations and Collaborations That Advance Endoscopic Care
Dublin, Ireland--(Newsfile Corp. - April 12, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announces that Medtronic plc...
Bausch Health to Announce First-Quarter 2024 Results on May 2
LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results...
Akanda Corp. Announces Plan to Integrate Technology Solutions to Capture UK Market
London, United Kingdom--(Newsfile Corp. - April 11, 2024) - On April 4, 2024, Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the...
Ovation Science Expands Market Reach with Exclusive Canadian License Agreement
VANCOUVER, BC and LAS VEGAS, NV / ACCESSWIRE / April 11, 2024 / (CSE:OVAT)(OTCQB:OVATF) - Ovation Science Inc. ("Ovation" or...
Throtle’s Data Pixel Technology to Enhance HealthVerity Media Measurement and Audience Manager Solutions
HealthVerity to enhance its Media Measurement and Audience Manager solutions using Throtle's data pixel technology for precise campaign targeting and...
Building a Better Future: Bristol Myers Squibb 2023 ESG Report
NORTHAMPTON, MA / ACCESSWIRE / April 11, 2024 / Bristol Myers Squibb Company:At Bristol Myers Squibb, our vision is to...
Akanda Corp. Announces Closing of the Sale of RPK
London, United Kingdom--(Newsfile Corp. - April 11, 2024) - On April 1, 2024, Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the...
Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan
LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC),...
Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market
$59 million financing includes participation from new Icelandic institutional and existing investors; Extends cash runway until 2H 2026 The Central...
CorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America Conference
BERKELEY HEIGHTS, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic...
SciSparc to Acquire AutoMax
TEL AVIV, Israel, April 11, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical...
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
Successful completion of TVGN 489’s proof-of-concept clinical trial suggested the ability to target and eliminate a virus in high-risk population...
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
Analysis of eligible1 patients from the sepsis Phase II study (NCT# NCT04612413) In accordance with the study protocol, the safety and...
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
STOUGHTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (the “Company”), a leading, diversified specialty pharmaceutical...